Genmab | GEN

Genmab traded at 2,578.00 this Friday March 24th, increasing 28.00 or 1.10 percent since the previous trading session. Looking back, over the last four weeks, Genmab gained 3.73 percent. Over the last 12 months, its price rose by 8.59 percent. Looking ahead, we forecast Genmab to be priced at 2,427.77 by the end of this quarter and at 2,186.42 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2,578.00
Daily Change
1.10%
Yearly
8.59%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Agios Pharmaceuticals 21.74 -0.24 -1.09% -24.49%
Almirall SA 8.71 -0.06 -0.68% -30.25%
Amgen 238.03 4.93 2.12% -0.32%
Amarin 1.53 0.01 0.66% -53.35%
argenx SE 335.00 2.10 0.63% 22.31%
Artemis Alpha 315.00 0 0% -11.02%
AstraZeneca 11,068.00 70.00 0.64% 12.45%
Bayer 55.44 -0.50 -0.89% -8.55%
Bluebird Bio 4.43 0.08 1.84% -11.04%
BioMarin Pharmaceutical 90.74 0.63 0.70% 14.83%
Exelixis 18.48 0.15 0.82% -15.54%
Fresenius Medical Care 37.08 -0.89 -2.34% -38.32%
Genmab 2,578.00 28.00 1.10% 8.59%
Galapagos 34.50 -0.26 -0.75% -38.87%
GN Store Nord 146.70 1.50 1.03% -52.39%
GRIFOLS 8.70 -0.31 -3.48% -43.79%
GlaxoSmithKline 1,401.20 -36.60 -2.55% -13.70%
Hikma Pharmaceutical 1,676.50 3.50 0.21% -18.26%
Immunogen 3.79 0.06 1.61% -11.03%
Insmed 16.46 0.05 0.30% -25.28%
Lonza Group 529.00 -9.80 -1.82% -19.19%
Merck 168.50 3.55 2.15% -6.41%
Novartis 76.40 0.60 0.79% -5.34%
Regeneron Pharmaceuticals 820.00 17.84 2.22% 20.58%
Roche Holding 258.25 -0.10 -0.04% -31.08%
Sanofi 96.88 1.04 1.09% 4.04%
Seattle Genetics 197.64 -0.46 -0.23% 42.88%
UCB 79.08 0.20 0.25% -26.20%
William Demant Holding 225.00 0.10 0.04% -20.49%


Genmab
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.